These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 24741312)

  • 1. Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system.
    Gomes MJ; Neves Jd; Sarmento B
    Int J Nanomedicine; 2014; 9():1757-69. PubMed ID: 24741312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nano-ART and NeuroAIDS.
    Das MK; Sarma A; Chakraborty T
    Drug Deliv Transl Res; 2016 Oct; 6(5):452-72. PubMed ID: 27137528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaches for CNS delivery of drugs - nose to brain targeting of antiretroviral agents as a potential attempt for complete elimination of major reservoir site of HIV to aid AIDS treatment.
    Gupta S; Kesarla R; Omri A
    Expert Opin Drug Deliv; 2019 Mar; 16(3):287-300. PubMed ID: 30779602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting anti-HIV drugs to the CNS.
    Rao KS; Ghorpade A; Labhasetwar V
    Expert Opin Drug Deliv; 2009 Aug; 6(8):771-84. PubMed ID: 19566446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Elvitegravir Nanoformulation Crosses the Blood-Brain Barrier and Suppresses HIV-1 Replication in Microglia.
    Gong Y; Zhi K; Nagesh PKB; Sinha N; Chowdhury P; Chen H; Gorantla S; Yallapu MM; Kumar S
    Viruses; 2020 May; 12(5):. PubMed ID: 32443728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral drug treatment of CNS HIV-1 infection.
    Yilmaz A; Price RW; Gisslén M
    J Antimicrob Chemother; 2012 Feb; 67(2):299-311. PubMed ID: 22160207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanostructured Delivery Systems: Augmenting the Delivery of Antiretroviral Drugs for Better Management of HIV/AIDS.
    Singh G; Pai RS; Mustafa S
    Crit Rev Ther Drug Carrier Syst; 2015; 32(6):503-33. PubMed ID: 26559551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticles and blood-brain barrier: the key to central nervous system diseases.
    Domínguez A; Suárez-Merino B; Goñi-de-Cerio F
    J Nanosci Nanotechnol; 2014 Jan; 14(1):766-79. PubMed ID: 24730296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain Macrophages in Simian Immunodeficiency Virus-Infected, Antiretroviral-Suppressed Macaques: a Functional Latent Reservoir.
    Avalos CR; Abreu CM; Queen SE; Li M; Price S; Shirk EN; Engle EL; Forsyth E; Bullock BT; Mac Gabhann F; Wietgrefe SW; Haase AT; Zink MC; Mankowski JL; Clements JE; Gama L
    mBio; 2017 Aug; 8(4):. PubMed ID: 28811349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. siRNA as a tool to improve the treatment of brain diseases: Mechanism, targets and delivery.
    Gomes MJ; Martins S; Sarmento B
    Ageing Res Rev; 2015 May; 21():43-54. PubMed ID: 25796492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Overview of Antiretroviral Agents for Treating HIV Infection in Paediatric Population.
    Melo R; Lemos A; Preto AJ; Bueschbell B; Matos-Filipe P; Barreto C; Almeida JG; Silva RDM; Correia JDG; Moreira IS
    Curr Med Chem; 2020; 27(5):760-794. PubMed ID: 30182840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-HIV drug distribution to the central nervous system.
    Thomas SA
    Curr Pharm Des; 2004; 10(12):1313-24. PubMed ID: 15134483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.
    Fiandra L; Capetti A; Sorrentino L; Corsi F
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):17-30. PubMed ID: 27832401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain.
    Wong HL; Chattopadhyay N; Wu XY; Bendayan R
    Adv Drug Deliv Rev; 2010 Mar; 62(4-5):503-17. PubMed ID: 19914319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective and anti-human immunodeficiency virus activity of minocycline.
    Zink MC; Uhrlaub J; DeWitt J; Voelker T; Bullock B; Mankowski J; Tarwater P; Clements J; Barber S
    JAMA; 2005 Apr; 293(16):2003-11. PubMed ID: 15855434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in antiretroviral drug delivery using nanotechnology.
    Mallipeddi R; Rohan LC
    Int J Nanomedicine; 2010 Aug; 5():533-47. PubMed ID: 20957115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 persistence in the central nervous system: viral and host determinants during antiretroviral therapy.
    Balcom EF; Roda WC; Cohen EA; Li MY; Power C
    Curr Opin Virol; 2019 Oct; 38():54-62. PubMed ID: 31390580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of nanotechnology in HIV/AIDS treatment: potential to overcome the viral reservoir challenge.
    Amiji MM; Vyas TK; Shah LK
    Discov Med; 2006 Aug; 6(34):157-62. PubMed ID: 17234137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing patterns in the neuropathogenesis of HIV during the HAART era.
    Langford TD; Letendre SL; Larrea GJ; Masliah E
    Brain Pathol; 2003 Apr; 13(2):195-210. PubMed ID: 12744473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticles and Its Implications in HIV/AIDS Therapy.
    Oti VB
    Curr Drug Discov Technol; 2020; 17(4):448-456. PubMed ID: 31250759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.